Tom York on Business: Breakthrough Status for Singlera Genomics' Pancreatic Cancer Test
San Diego biotech Singlera Genomics said the FDA has granted Breakthrough Device Designation for its new assay, which detects deadily pancreatic ductal adenocarcinoma in high-risk patients.